Participant flow

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) · Source last updated 2026-01-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Part A: 10 milligrams per kilogram (mg/kg) ramucirumab administered every 2 weeks intravenously (IV) in combination with 150 mg erlotinib daily orally. Participants may continue to receive treatment until discontinuation criteria are met.

   id

   FG000

   title

   Part A: Ramucirumab + Erlotinib

2. description

   Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally. Participants may continue to receive treatment until discontinuation criteria are met.

   id

   FG001

   title

   Part B: Ramucirumab+ Erlotinib

3. description

   Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally. Participants may continue to receive treatment until discontinuation criteria are met.

   id

   FG002

   title

   Part B: Placebo+ Erlotinib

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         14

      3. group Id

         FG002

         num Subjects

         9

      type

      Withdrawal by Subject

   2. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         2

      3. group Id

         FG002

         num Subjects

         0

      type

      Other

   3. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         3

      3. group Id

         FG002

         num Subjects

         0

      type

      Did not receive study treatment

   4. reasons

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         64

      3. group Id

         FG002

         num Subjects

         43

      type

      Alive on study treatment

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         14

      2. group Id

         FG001

         num Subjects

         224

      3. group Id

         FG002

         num Subjects

         225

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         14

      2. group Id

         FG001

         num Subjects

         221

      3. group Id

         FG002

         num Subjects

         225

      type

      Received at Least One Dose of Study Drug

   3. achievements

      1. group Id

         FG000

         num Subjects

         10

      2. group Id

         FG001

         num Subjects

         141

      3. group Id

         FG002

         num Subjects

         173

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         4

      2. group Id

         FG001

         num Subjects

         83

      3. group Id

         FG002

         num Subjects

         52

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

This study consists of 3 parts: * Part A: Open-label. * Part B: Randomized, double-blind and placebo-controlled. * Part C: Open-label. Part C data will be reported after study completion.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice